The multi-year agreement aims to use Outset Medical’s Tablo Hemodialysis System as a home dialysis alternative across the 33 states in which U.S. Renal Care delivers care
Outset Medical’s Tablo Hemodialysis System. (Credit: Business Wire)
Outset Medical, a dialysis-focused medical technology company, has partnered with privately held kidney care provider U.S. Renal Care to accelerate and grow home haemodialysis across the US.
The multi-year agreement aims to use Outset Medical’s Tablo Hemodialysis System as an option for home dialysis across the 33 states in which U.S. Renal Care delivers care.
The Tablo system secured the US Food and Drug Administration (FDA) clearance in April 2020 for patient use in the home.
The haemodialysis system is designed to enhance the dialysis experience for patients and operationally streamlines it for clinicians.
The single enterprise solution can be used across the continuum of care using only a regular electrical outlet and tap water to deliver dialysis anytime, anywhere, and by anybody.
Outset Medical said that increasing treatment choices in the communities served by U.S. Renal Care will help meet the growing demand of dialysis patients seeking treatment at home.
U.S. Renal Care co-chief operating officer Steve Nottingham said: “We strive to provide patients with new and innovative solutions that deliver the best outcomes possible.
“We have seen success using the Tablo system in our home haemodialysis programme, and with our multi-year agreement with Outset, can continue providing our patients and caregivers access to lifesaving dialysis treatment in an easy-to-operate system, all in the comfort of their own homes.”
Tablo was created to simplify and lower the cost of dialysis treatment. Patients and doctors can avoid costly clinic infrastructure using this mobile dialysis system.
The system can work as a mobile dialysis clinic using its capabilities like wireless data, sensor-based automation, and an animated touchscreen.
Outset Medical chair and CEO Leslie Trigg said: “Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyse.
“Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyze to survive. We are pleased to partner with U.S. Renal Care to advance this mission.”
In November 2021, the medical technology firm received the FDA 510(k) clearance for a new method to sterilise cartridges used in its Tablo Hemodialysis System.